Theravance Biopharma, Inc. Announces Top-line Results From Phase 2 Study Of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due To Covid-19

Excerpt from the Press Release:

DUBLIN and SOUTH SAN FRANCISCO, Calif., June 21, 2021 /PRNewswire/ — Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, today announced top-line results from its Phase 2 study of 3 mg once-daily nezulcitinib compared to placebo, each in combination with standard of care. Nezulcitinib is an investigational, inhaled, lung-selective, pan-Janus kinase (JAK) inhibitor in development for hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation. 

“Since learning of the extensive respiratory complications in severe COVID-19, we have worked to advance the science behind inhaled lung-selective JAK inhibitors in critical diseases like COVID-19,” said Rick E Winningham, Chief Executive Officer, Theravance Biopharma. “Even though this Phase 2 study, enrolling more than 200 patients, did not meet the primary endpoint, we are encouraged by the trend in the pre-specified analysis of the 28-day mortality rate in the intent-to-treat population. We are grateful to the patients and their families, our research partners, the clinical investigators, and our team at Theravance Biopharma for their important contributions.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release